{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:57:34Z","timestamp":1792180654691,"version":"4.4.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Givinostat is a novel histone deacetylase inhibitor, which was approved by the US Food and Drug Administration (FDA) in 2024 for treatment of Duchenne muscular dystrophy (DMD). This early post-marketing pharmacovigilance study aimed to explore the adverse events (AEs) caused by givinostat through data mining of the US FDA Adverse Event Reporting System (FAERS), and provide reference for clinical safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data of givinostat were collected from the FAERS database covering the period from the first quarter of 2024 to the fourth quarter of 2025. Disproportionality analyses were employed to quantify the associated AE signals of givinostat and detect the risk signals from the data in the FAERS database. Four algorithms, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM), were used to detect the risk signals from the data in the FAERS database. The definition relied on system organ class (SOCs) and preferred terms (PTs) by the Medical Dictionary for Regulatory Activities (MedDRA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 402 reports of givinostat were identified as the \u201cprimary suspected (PS)\u201d AEs. Givinostat-associated AEs were identified across 23 organ systems. Significant disproportionality PTs simultaneously meeting the criteria of all four algorithms. Expected AEs, including decreased platelet count, diarrhoea, and increased blood triglycerides, were identified. Unexpected significant signals such as lower limb fracture, femur fracture, anger, and mood swings were also detected, although these are likely heavily confounded by the underlying disease progression and concurrent corticosteroid use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Based on early post-marketing data, this study provides a preliminary real-world safety assessment of givinostat. In addition to validating known hematological and gastrointestinal toxicities, it identifies potential signals for orthopedic complications, psychiatric events, and hypertriglyceridemia. While these novel signals are heavily confounded by the natural history of DMD and chronic corticosteroid exposure, they warrant continuous multidisciplinary monitoring. As hypothesis-generating signals derived from spontaneous reports, these initial findings require future prospective validation. They expand the current understanding of givinostat\u2019s safety profile and highlight the necessity for continuous pharmacovigilance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1861893","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:35:03Z","timestamp":1783582503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world safety profile of givinostat: an early post-marketing pharmacovigilance study based on the FAERS database"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiahao","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Affiliated Hospital 6 of Nantong University","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Affiliated Hospital 6 of Nantong University","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Affiliated Hospital 6 of Nantong University","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Affiliated Hospital 6 of Nantong University","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Affiliated Hospital 6 of Nantong University","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjian","family":"Ji","sequence":"additional","affiliation":[{"name":"Yancheng City Therapeutic Drug Precision Testing Engineering Center, School of Pharmacy, Jiangsu Medical College","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchao","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Affiliated Hospital 6 of Nantong University","place":["Yancheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1514898","DOI":"10.3389\/fcell.2024.1514898","article-title":"Histone deacetylase inhibition with givinostat: a multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophy","volume":"12","author":"Aartsma-Rus","year":"2024","journal-title":"Front. Cell Developmental Biology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mus.28482","article-title":"Advances in MicroRNAs in pathophysiology of duchenne muscular dystrophy","volume":"72","author":"Aguilar","year":"2025","journal-title":"Muscle and Nerve"},{"key":"B3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC. CardioOncology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13760-024-02600-2","article-title":"If you cannot measure it, you cannot improve it. Outcome measures in Duchenne muscular dystrophy: current and future perspectives","volume":"125","author":"Benemei","year":"2025","journal-title":"Acta Neurol. Belg."},{"key":"B5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disorders NMD"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1183101","DOI":"10.3389\/fphys.2023.1183101","article-title":"Duchenne muscular dystrophy: disease mechanism and therapeutic strategies","volume":"14","author":"Bez Batti Angulski","year":"2023","journal-title":"Front. Physiology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet. Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2010-11-318055","article-title":"Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia","volume":"117","author":"Bishton","year":"2011","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1496870","DOI":"10.3389\/fphys.2024.1496870","article-title":"Molecular pathways involved in the control of contractile and metabolic properties of skeletal muscle fibers as potential therapeutic targets for Duchenne muscular dystrophy","volume":"15","author":"Bonato","year":"2024","journal-title":"Front. Physiology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1007\/s00415-023-11796-x","article-title":"Duchenne muscular dystrophy: pathogenesis and promising therapies","volume":"270","author":"Chang","year":"2023","journal-title":"J. Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13023-026-04267-9","article-title":"Real-world safety assessment of burosumab: a pharmacovigilance study utilizing the FDA adverse event reporting system","volume":"21","author":"Chen","year":"2026","journal-title":"Orphanet Journal Rare Diseases"},{"key":"B12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jaad.2025.09.039","article-title":"Real-world safety of apremilast: a pharmacovigilance analysis using the FDA adverse event reporting system (FAERS)","volume":"94","author":"Chen","year":"2026","journal-title":"J. Am. Acad. Dermatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000547936","article-title":"Safety and efficacy of givinostat for patients with muscular dystrophy: a systematic review","volume":"110","author":"Das","year":"2025","journal-title":"Pharmacology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Reviews. Dis. Primers"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1038\/s41598-025-92330-z","article-title":"Analysis and mining of dupilumab adverse events based on FAERS database","volume":"15","author":"Gao","year":"2025","journal-title":"Sci. Reports"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1521358","DOI":"10.3389\/fphar.2025.1521358","article-title":"Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database","volume":"16","author":"He","year":"2025","journal-title":"Front. Pharmacology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The weber effect and the United States food and drug Administration's adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Safety"},{"key":"B18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s13023-025-03934-7","article-title":"Evaluation and study of adverse reactions to imiglucerase based on the FAERS database","volume":"20","author":"Hong","year":"2025","journal-title":"Orphanet Journal Rare Diseases"},{"key":"B19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/s12967-024-05494-z","article-title":"Exploring lipin1 as a promising therapeutic target for the treatment of Duchenne muscular dystrophy","volume":"22","author":"Jama","year":"2024","journal-title":"J. Translational Medicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jaad.2025.02.031","article-title":"Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database","volume":"92","author":"Joshi","year":"2025","journal-title":"J. Am. Acad. Dermatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2026.02.046","article-title":"Drug-associated paronychia: pharmacovigilance signals from the U.S. food and drug administration adverse event reporting system (FAERS) and the canada vigilance adverse reaction database (CVARD)","volume":"95","author":"Le","year":"2026","journal-title":"J. Am. Acad. Dermatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1498814","DOI":"10.3389\/fphar.2025.1498814","article-title":"Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jaad.2025.08.003","article-title":"A real-world analysis of adverse event signals of cognitive and communication disorder in patients treated with janus kinase inhibitors based on the FAERS database","volume":"93","author":"Lin","year":"","journal-title":"J. Am. Acad. Dermatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1714173","DOI":"10.3389\/fphar.2025.1714173","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab","volume":"16","author":"Lin","year":"","journal-title":"Front. Pharmacology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1097\/js9.0000000000003609","article-title":"Drug-induced perioperative malignant hyperthermia: a real-world study based on the food and drug administration adverse event reporting system (FAERS) database","volume":"112","author":"Lu","year":"2026","journal-title":"Int. Journal Surgery Lond. Engl."},{"key":"B28","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/s1474-4422(22)00125-9","article-title":"Emerging therapies for Duchenne muscular dystrophy","volume":"21","author":"Markati","year":"2022","journal-title":"Lancet. Neurology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/s0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Medicine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s1474-4422(24)00036-x","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet. Neurology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles","volume":"37","author":"Michel","year":"2017","journal-title":"Clin. Drug Investigation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J. Clinical Oncology Official Journal Am. Soc. Clin. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jbmr.541","article-title":"Adverse effects of hyperlipidemia on bone regeneration and strength","volume":"27","author":"Pirih","year":"2012","journal-title":"J. Bone Mineral Research The Official Journal Am. Soc. Bone Mineral Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12916-024-03537-2","article-title":"Differences in hypersensitivity reactions and gadolinium deposition disease\/symptoms associated with gadolinium exposure to gadolinium-based contrast agents: new insights based on global databases VigiBase, FAERS, and IQVIA-MIDAS","volume":"22","author":"Qu","year":"2024","journal-title":"BMC Medicine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","article-title":"Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results","volume":"108","author":"Rai","year":"2023","journal-title":"Haematologica"},{"key":"B37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/dmcn.12922","article-title":"Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations","volume":"58","author":"Ricotti","year":"2016","journal-title":"Dev. Medicine Child Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3892\/mmr.2015.3472","article-title":"Lipid metabolism disorders and bone dysfunction--interrelated and mutually regulated (review)","volume":"12","author":"Tian","year":"2015","journal-title":"Mol. Medicine Reports"},{"key":"B39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.tins.2012.04.004","article-title":"The dystrophin-glycoprotein complex in brain development and disease","volume":"35","author":"Waite","year":"2012","journal-title":"Trends Neurosciences"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0330769","DOI":"10.1371\/journal.pone.0330769","article-title":"Remimazolam's clinical application and safety: a signal detection analysis based on FAERS data and literature support","volume":"20","author":"Ye","year":"2025","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Reports"},{"key":"B42","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1186\/s13018-023-04275-6","article-title":"Association between triglyceride-glucose index and bone mineral density in US adults: a cross sectional study","volume":"18","author":"Zhan","year":"2023","journal-title":"J. Orthopaedic Surgery Research"},{"key":"B43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","article-title":"Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA adverse event reporting system database","volume":"22","author":"Zhou","year":"2024","journal-title":"BMC Medicine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"103160","DOI":"10.1016\/j.eclinm.2025.103160","article-title":"Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study","volume":"82","author":"Zhu","year":"2025","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1861893\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:35:04Z","timestamp":1783582504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1861893\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":44,"alternative-id":["10.3389\/fphar.2026.1861893"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1861893","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1861893"}}